Compare CPHC & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPHC | RLYB |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 86.6M |
| IPO Year | 2016 | 2021 |
| Metric | CPHC | RLYB |
|---|---|---|
| Price | $15.55 | $16.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.3K | ★ 38.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.03 | ★ 6.16 |
| Revenue | ★ $59,227,000.00 | $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $508.75 | ★ N/A |
| Revenue Growth | 0.14 | ★ 43.00 |
| 52 Week Low | $14.49 | $0.40 |
| 52 Week High | $17.95 | $17.57 |
| Indicator | CPHC | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 54.70 |
| Support Level | $15.13 | $15.60 |
| Resistance Level | $15.74 | $16.50 |
| Average True Range (ATR) | 0.30 | 0.46 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 8.42 | 27.42 |
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the real estate development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.